ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials.
Location: United Kingdom, England, London
Employees: 11-50
Founded date: 2020
Investors 1
| Date | Name | Website |
| 23.02.2022 | Disruptive... | disruptive... |
Mentions in press and media 4
| Date | Title | Description |
| 15.08.2024 | ViroCell Biologics Closes Convertible Note Financing | ViroCell Biologics, a London, UK- and NYC-based cell and gene therapy contract development and manufacturing organization, raised an undisclosed amount in convertible note funding. The round was led by First Light Asset Management LLC, join... |
| 02.11.2023 | ViroCell gets UK green light to produce viral vectors at children’s hospital facility | ViroCell Biologics has secured approval from the U.K.’s healthcare regulator to begin manufacturing and exporting the viral vector products it makes at a leading children’s hospital. The London- and New York-based CDMO was given the green ... |
| 02.11.2023 | ViroCell tackles CGT bottleneck with MHRA approval | ViroCell said MHRA’s manufacturing approval will allow it to produce viral vectors at Great Ormond Street Hospital (GOSH) for CGT clinical trials. Contract development manufacturing organization (CDMO) ViroCell Biologics said the viral vec... |
| 01.11.2023 | ViroCell to operate from a London facility to manufacture viral vectors for clinical trials | Viral vector manufacturer ViroCell Biologics is leasing its first-ever facility — located at Great Ormond Street Hospital in London — so it can offer its services for clinical research. ViroCell worked with the hospital for about 18 months... |